Stomach acid–blocking proton pump inhibitor drugs—PPIs with brand names like Prilosec, Prevacid, Nexium, Protonix, and AcipHex—appear to significantly increase the risk of bone fractures.
Acid Reflux Medicine May Cause Osteoporosis
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
Nearly one in five adults in the world may have osteoporosis. That’s hundreds of millions of people. The word “osteoporosis” literally means porous bone. Now, most of our bone is actually porous to begin with. This is what normal bone looks like inside, but this is osteoporosis.
Bone mineral density is considered to be the standard measure for the diagnosis of osteoporosis. Although the bone mineral density cut-off for an osteoporosis diagnosis is kind of arbitrary, using the standard definition, osteoporosis may affect about one in 10 women by age 60, two in 10 by age 70, four in 10 by age 80, and six or seven out of 10 by age 90. Osteoporosis is typically thought of as a disease in women, but one-third of hip fractures occur in men. The lifetime risk for osteoporotic fractures (for 50-year-old white women and men) are 40 percent and 13 percent, respectively.
The good news is that osteoporosis need not occur. Based on a study of the largest twin registry in the world, less than 30 percent of osteoporotic fracture risk is heritable, leading the researchers to conclude, “Prevention of fractures [even] in the oldest elderly should focus on lifestyle interventions.” This is consistent with the enormous variation in hip fracture rates around the world, with the incidence of hip fracture varying 10-fold, or even 100-fold between countries, suggesting that excessive bone loss is not just an inevitable consequence of aging.
The U.S. Preventive Services Task Force, an independent scientific panel that sets evidence-based, clinical prevention guidelines, recommends osteoporosis screening (such as a DXA bone mineral density scan) for all women aged 65 years and older, and potentially starting even earlier than 65 for women at increased risk (such as having a parental history of hip fracture, being a smoker or an excessive alcohol consumer, or having low body weight). What should you do if you’re diagnosed, or more importantly, what should you do to never be diagnosed? Before exploring the drugs on offering to treat osteoporosis, there are some drugs that may cause it, so let’s start there.
Stomach acid-blocking “proton pump inhibitor” drugs, so-called PPIs—with brand names like Prilosec, Prevacid, Nexium, Protonix, and AcipHex—are among the most popular drugs in the world, raking in billions of dollars a year. But then in 2006, two observational studies out of Europe suggested an association between intake of this class of drugs and increased risk of hip fracture. And by 2010, the growing evidence forced the U.S. Food and Drug Administration to issue a safety alert implicating PPI use with fractures of the hip, wrist, and spine. By now, there’ve been dozens of such studies involving more than two million people who, overall, show higher hip fracture rates among both long- and short-term users at all dose levels.
The irony is that most people taking these drugs shouldn’t even be on them in the first place. These PPIs are only FDA-approved for 10 days of use for the treatment of H. pylori, up to two weeks for heartburn, up to eight weeks for acid reflux disease, and for two to six months for ulcers. Yet, in a community survey, most users remained on these drugs for more than a year, and more than 60 percent of patients were taking them for inappropriate reasons, often wrongly prescribed for “indigestion,” for instance.
Calls to stop this massive overuse from regulatory authorities have fallen on deaf doctor ears. And now that they’re available over the counter, the problem of overuse may have gotten even worse. They can be hard to stop taking, since many patients experience withdrawal symptoms that can last for weeks. In fact, if you take normal healthy volunteers without any symptoms, and put them on these drugs for two months, and then covertly switch them to a placebo without their knowledge, all of a sudden they can develop acid-related symptoms, such as heartburn or acid regurgitation. So, ending up worse off than they were before they even started taking the drugs.
In addition to bone fractures, this class of drugs has also been linked to increased risk of other possible long-term adverse effects, such as pneumonia, intestinal infections, kidney failure, stomach cancer, and cardiovascular disease. In fact, the blood vessel effects could explain the case report “Abrupt-Onset, Profound Erectile Dysfunction in a Healthy Young Man After Initiating Over-the-Counter Omeprazole” (which is Prilosec). Oh, and also premature death.
There are individuals with conditions like Zollinger-Ellison syndrome—stricken with tumors that can cause excess stomach acid secretion—for whom the risk versus benefit of long-term use may be acceptable. But that’s a far cry from the 100 million PPIs prescribed annually in the United States alone.
To deal with acid reflux without drugs, recommendations include weight loss, smoking cessation, avoiding fatty meals (especially within two to three hours of bedtime), increased fiber consumption, and, overall, a more plant-based diet––because nonvegetarianism is associated with twice the odds of acid reflux-induced inflammation.
Other classes of drugs that have been associated with hip fracture risk include antidepressants, anti-Parkinson’s drugs, antipsychotics, anti-anxiety drugs, oral corticosteroids, and the other major class of heartburn drugs, the H2 blockers, such as Pepcid, Zantac, Tagamet, and Axid.
Please consider volunteering to help out on the site.
- Salari N, Ghasemi H, Mohammadi L, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021;16(1):609.
- Sieberath A, Della Bella E, Ferreira AM, Gentile P, Eglin D, Dalgarno K. A comparison of osteoblast and osteoclast in vitro co-culture models and their translation for preclinical drug testing applications. Int J Mol Sci. 2020;21(3):912.
- Unnanuntana A, Gladnick BP, Donnelly E, Lane JM. The assessment of fracture risk. J Bone Joint Surg Am. 2010;92(3):743-753.
- Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. J Intern Med. 2015;277(6):650-661.
- Gupta T, Das N, Imran S. The prevention and therapy of osteoporosis: a review on emerging trends from hormonal therapy to synthetic drugs to plant-based bioactives. J Diet Suppl. 2019;16(6):699-713.
- Sahota O, Masud T. Osteoporosis: fact, fiction, fallacy and the future. Age Ageing. 1999;28(5):425-428.
- Michaëlsson K, Melhus H, Ferm H, Ahlbom A, Pedersen NL. Genetic liability to fractures in the elderly. Arch Intern Med. 2005;165(16):1825-1830.
- Kanis JA, Odén A, McCloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239-2256.
- US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(24):2521-2531.
- Luo H, Fan Q, Xiao S, Chen K. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital. BMC Health Serv Res. 2018;18(1):537.
- Moayyedi P, Lewis MA. Proton pump inhibitors and dementia: deciphering the data. Am J Gastroenterol. 2017;112(12):1809-1811.
- Savarino E, Marabotto E, Zentilin P, et al. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opin Drug Saf. 2018;17(8):785-794.
- Ayoub J, White ND. GERD management: the case for lifestyle in an era of PPIs. Am J Lifestyle Med. 2017;11(1):24-28.
- Poly TN, Islam MM, Yang HC, Wu CC, Li YCJ. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019;30(1):103-114.
- Safer DJ. Overprescribed medications for US adults: four major examples. J Clin Med Res. 2019;11(9):617-622.
- Abrahami D, McDonald EG, Schnitzer M, Azoulay L. Trends in prescribing patterns of proton pump inhibitors surrounding new guidelines. Ann Epidemiol. 2021;55:24-26.
- Sheikh I, Waghray A, Waghray N, Dong C, Wolfe MM. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2014;109(6):789-794.
- Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80-87, 87.e1.
- Salvo EM, Ferko NC, Cash SB, Gonzalez A, Kahrilas PJ. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther. 2021;54(2):129-143.
- Xun X, Yin Q, Fu Y, He X, Dong Z. Proton pump inhibitors and the risk of community-acquired pneumonia: an updated meta-analysis. Ann Pharmacother. 2022;56(5):524-532.
- D'Silva KM, Mehta R, Mitchell M, et al. Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis [published online ahead of print, 2021 Jan 16]. Clin Microbiol Infect. 2021;S1198-743X(21)00035-5.
- Vengrus CS, Delfino VD, Bignardi PR. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease. Minerva Urol Nephrol. 2021;73(4):462-470.
- Guo H, Zhang R, Zhang P, et al. Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis. Front Pharmacol. 2023;14:1129948.
- Sun S, Cui Z, Zhou M, et al. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis. Neurogastroenterol Motil. 2017;29(2).
- Perry TW. Abrupt-onset, profound erectile dysfunction in a healthy young man after initiating over-the-counter omeprazole: a case report. J Med Case Rep. 2021;15(1):360.
- Ben-Eltriki M, Green CJ, Maclure M, Musini V, Bassett KL, Wright JM. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence. Pharmacol Res Perspect. 2020;8(5):e00651.
- Ren D, Gurney E, Hornecker JR. Appropriate Use and Stewardship of Proton-Pump Inhibitors. US Pharm. 2019:44(12):25-31.
- Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016;14(2):175-182.e1-3.
- Fox M, Barr C, Nolan S, Lomer M, Anggiansah A, Wong T. The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms. Clin Gastroenterol Hepatol. 2007;5(4):439-444.
- Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-328.
- Newberry C, Lynch K. The role of diet in the development and management of gastroesophageal reflux disease: why we feel the burn. J Thorac Dis. 2019;11(Suppl 12):S1594-S1601.
- Jung JG, Kang HW. Vegetarianism and the risk of gastroesophageal reflux disease. In: Vegetarian and Plant-Based Diets in Health and Disease Prevention. Elsevier; 2017:463-472.
- Jung JG, Kang HW, Hahn SJ, et al. Vegetarianism as a protective factor for reflux esophagitis: a retrospective, cross-sectional study between Buddhist priests and general population. Dig Dis Sci. 2013;58(8):2244-2252.
- Mortensen SJ, Mohamadi A, Wright CL, et al. Medications as a risk factor for fragility hip fractures: a systematic review and meta-analysis. Calcif Tissue Int. 2020;107(1):1-9.
Motion graphics by Avo Media
Below is an approximation of this video’s audio content. To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video.
Nearly one in five adults in the world may have osteoporosis. That’s hundreds of millions of people. The word “osteoporosis” literally means porous bone. Now, most of our bone is actually porous to begin with. This is what normal bone looks like inside, but this is osteoporosis.
Bone mineral density is considered to be the standard measure for the diagnosis of osteoporosis. Although the bone mineral density cut-off for an osteoporosis diagnosis is kind of arbitrary, using the standard definition, osteoporosis may affect about one in 10 women by age 60, two in 10 by age 70, four in 10 by age 80, and six or seven out of 10 by age 90. Osteoporosis is typically thought of as a disease in women, but one-third of hip fractures occur in men. The lifetime risk for osteoporotic fractures (for 50-year-old white women and men) are 40 percent and 13 percent, respectively.
The good news is that osteoporosis need not occur. Based on a study of the largest twin registry in the world, less than 30 percent of osteoporotic fracture risk is heritable, leading the researchers to conclude, “Prevention of fractures [even] in the oldest elderly should focus on lifestyle interventions.” This is consistent with the enormous variation in hip fracture rates around the world, with the incidence of hip fracture varying 10-fold, or even 100-fold between countries, suggesting that excessive bone loss is not just an inevitable consequence of aging.
The U.S. Preventive Services Task Force, an independent scientific panel that sets evidence-based, clinical prevention guidelines, recommends osteoporosis screening (such as a DXA bone mineral density scan) for all women aged 65 years and older, and potentially starting even earlier than 65 for women at increased risk (such as having a parental history of hip fracture, being a smoker or an excessive alcohol consumer, or having low body weight). What should you do if you’re diagnosed, or more importantly, what should you do to never be diagnosed? Before exploring the drugs on offering to treat osteoporosis, there are some drugs that may cause it, so let’s start there.
Stomach acid-blocking “proton pump inhibitor” drugs, so-called PPIs—with brand names like Prilosec, Prevacid, Nexium, Protonix, and AcipHex—are among the most popular drugs in the world, raking in billions of dollars a year. But then in 2006, two observational studies out of Europe suggested an association between intake of this class of drugs and increased risk of hip fracture. And by 2010, the growing evidence forced the U.S. Food and Drug Administration to issue a safety alert implicating PPI use with fractures of the hip, wrist, and spine. By now, there’ve been dozens of such studies involving more than two million people who, overall, show higher hip fracture rates among both long- and short-term users at all dose levels.
The irony is that most people taking these drugs shouldn’t even be on them in the first place. These PPIs are only FDA-approved for 10 days of use for the treatment of H. pylori, up to two weeks for heartburn, up to eight weeks for acid reflux disease, and for two to six months for ulcers. Yet, in a community survey, most users remained on these drugs for more than a year, and more than 60 percent of patients were taking them for inappropriate reasons, often wrongly prescribed for “indigestion,” for instance.
Calls to stop this massive overuse from regulatory authorities have fallen on deaf doctor ears. And now that they’re available over the counter, the problem of overuse may have gotten even worse. They can be hard to stop taking, since many patients experience withdrawal symptoms that can last for weeks. In fact, if you take normal healthy volunteers without any symptoms, and put them on these drugs for two months, and then covertly switch them to a placebo without their knowledge, all of a sudden they can develop acid-related symptoms, such as heartburn or acid regurgitation. So, ending up worse off than they were before they even started taking the drugs.
In addition to bone fractures, this class of drugs has also been linked to increased risk of other possible long-term adverse effects, such as pneumonia, intestinal infections, kidney failure, stomach cancer, and cardiovascular disease. In fact, the blood vessel effects could explain the case report “Abrupt-Onset, Profound Erectile Dysfunction in a Healthy Young Man After Initiating Over-the-Counter Omeprazole” (which is Prilosec). Oh, and also premature death.
There are individuals with conditions like Zollinger-Ellison syndrome—stricken with tumors that can cause excess stomach acid secretion—for whom the risk versus benefit of long-term use may be acceptable. But that’s a far cry from the 100 million PPIs prescribed annually in the United States alone.
To deal with acid reflux without drugs, recommendations include weight loss, smoking cessation, avoiding fatty meals (especially within two to three hours of bedtime), increased fiber consumption, and, overall, a more plant-based diet––because nonvegetarianism is associated with twice the odds of acid reflux-induced inflammation.
Other classes of drugs that have been associated with hip fracture risk include antidepressants, anti-Parkinson’s drugs, antipsychotics, anti-anxiety drugs, oral corticosteroids, and the other major class of heartburn drugs, the H2 blockers, such as Pepcid, Zantac, Tagamet, and Axid.
Please consider volunteering to help out on the site.
- Salari N, Ghasemi H, Mohammadi L, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021;16(1):609.
- Sieberath A, Della Bella E, Ferreira AM, Gentile P, Eglin D, Dalgarno K. A comparison of osteoblast and osteoclast in vitro co-culture models and their translation for preclinical drug testing applications. Int J Mol Sci. 2020;21(3):912.
- Unnanuntana A, Gladnick BP, Donnelly E, Lane JM. The assessment of fracture risk. J Bone Joint Surg Am. 2010;92(3):743-753.
- Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. J Intern Med. 2015;277(6):650-661.
- Gupta T, Das N, Imran S. The prevention and therapy of osteoporosis: a review on emerging trends from hormonal therapy to synthetic drugs to plant-based bioactives. J Diet Suppl. 2019;16(6):699-713.
- Sahota O, Masud T. Osteoporosis: fact, fiction, fallacy and the future. Age Ageing. 1999;28(5):425-428.
- Michaëlsson K, Melhus H, Ferm H, Ahlbom A, Pedersen NL. Genetic liability to fractures in the elderly. Arch Intern Med. 2005;165(16):1825-1830.
- Kanis JA, Odén A, McCloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239-2256.
- US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(24):2521-2531.
- Luo H, Fan Q, Xiao S, Chen K. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital. BMC Health Serv Res. 2018;18(1):537.
- Moayyedi P, Lewis MA. Proton pump inhibitors and dementia: deciphering the data. Am J Gastroenterol. 2017;112(12):1809-1811.
- Savarino E, Marabotto E, Zentilin P, et al. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opin Drug Saf. 2018;17(8):785-794.
- Ayoub J, White ND. GERD management: the case for lifestyle in an era of PPIs. Am J Lifestyle Med. 2017;11(1):24-28.
- Poly TN, Islam MM, Yang HC, Wu CC, Li YCJ. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019;30(1):103-114.
- Safer DJ. Overprescribed medications for US adults: four major examples. J Clin Med Res. 2019;11(9):617-622.
- Abrahami D, McDonald EG, Schnitzer M, Azoulay L. Trends in prescribing patterns of proton pump inhibitors surrounding new guidelines. Ann Epidemiol. 2021;55:24-26.
- Sheikh I, Waghray A, Waghray N, Dong C, Wolfe MM. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2014;109(6):789-794.
- Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80-87, 87.e1.
- Salvo EM, Ferko NC, Cash SB, Gonzalez A, Kahrilas PJ. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther. 2021;54(2):129-143.
- Xun X, Yin Q, Fu Y, He X, Dong Z. Proton pump inhibitors and the risk of community-acquired pneumonia: an updated meta-analysis. Ann Pharmacother. 2022;56(5):524-532.
- D'Silva KM, Mehta R, Mitchell M, et al. Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis [published online ahead of print, 2021 Jan 16]. Clin Microbiol Infect. 2021;S1198-743X(21)00035-5.
- Vengrus CS, Delfino VD, Bignardi PR. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease. Minerva Urol Nephrol. 2021;73(4):462-470.
- Guo H, Zhang R, Zhang P, et al. Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis. Front Pharmacol. 2023;14:1129948.
- Sun S, Cui Z, Zhou M, et al. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis. Neurogastroenterol Motil. 2017;29(2).
- Perry TW. Abrupt-onset, profound erectile dysfunction in a healthy young man after initiating over-the-counter omeprazole: a case report. J Med Case Rep. 2021;15(1):360.
- Ben-Eltriki M, Green CJ, Maclure M, Musini V, Bassett KL, Wright JM. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence. Pharmacol Res Perspect. 2020;8(5):e00651.
- Ren D, Gurney E, Hornecker JR. Appropriate Use and Stewardship of Proton-Pump Inhibitors. US Pharm. 2019:44(12):25-31.
- Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016;14(2):175-182.e1-3.
- Fox M, Barr C, Nolan S, Lomer M, Anggiansah A, Wong T. The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms. Clin Gastroenterol Hepatol. 2007;5(4):439-444.
- Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-328.
- Newberry C, Lynch K. The role of diet in the development and management of gastroesophageal reflux disease: why we feel the burn. J Thorac Dis. 2019;11(Suppl 12):S1594-S1601.
- Jung JG, Kang HW. Vegetarianism and the risk of gastroesophageal reflux disease. In: Vegetarian and Plant-Based Diets in Health and Disease Prevention. Elsevier; 2017:463-472.
- Jung JG, Kang HW, Hahn SJ, et al. Vegetarianism as a protective factor for reflux esophagitis: a retrospective, cross-sectional study between Buddhist priests and general population. Dig Dis Sci. 2013;58(8):2244-2252.
- Mortensen SJ, Mohamadi A, Wright CL, et al. Medications as a risk factor for fragility hip fractures: a systematic review and meta-analysis. Calcif Tissue Int. 2020;107(1):1-9.
Motion graphics by Avo Media
Republishing "Acid Reflux Medicine May Cause Osteoporosis"
You may republish this material online or in print under our Creative Commons licence. You must attribute the article to NutritionFacts.org with a link back to our website in your republication.
If any changes are made to the original text or video, you must indicate, reasonably, what has changed about the article or video.
You may not use our material for commercial purposes.
You may not apply legal terms or technological measures that restrict others from doing anything permitted here.
If you have any questions, please Contact Us
Acid Reflux Medicine May Cause Osteoporosis
LicenseCreative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Content URLDoctor's Note
I recently gave a webinar on osteoporosis, and you can watch the whole recording now. Check out my previous video on osteoporosis: Fall Prevention Is the Most Important Thing for Preventing Osteoporosis Bone Fractures.
How Well Do Medicines Like Fosamax Work to Treat Osteoporosis? Watch the video to find out. What are the Side Effects of Osteoporosis Medications Like Fosamax, Boniva, and Reclast? Check out the video.
What about calcium supplements? See my videos Are Calcium Supplements Safe? and Are Calcium Supplements Effective?
What about drinking milk? See my video Is Milk Good for Our Bones?
What are Three Reasons Fruits and Vegetables May Reduce Osteoporosis Risk? What about onions and tomatoes for osteoporosis? Check out the videos.
If you haven't yet, you can subscribe to our free newsletter. With your subscription, you'll also get notifications for just-released blogs and videos. Check out our information page about our translated resources.